论文部分内容阅读
目的评价甲胎蛋白异质体3(AFP-L3)、高尔基体蛋白73(GP73)血清水平检测在原发性肝细胞癌(HCC)射频消融治疗应答中的应用效果。方法收集入院前未接受过治疗的原发性肝癌患者34例(A组);肝炎、肝硬化患者46例(B组);健康体检者30例(C组)。A组患者经治疗后复查患者34例(D组)。检测总AFP和AFP-L3的含量,计算AFP-L3百分比;血清GP73采用酶联免疫法测定。结果原发肝癌患者治疗前施行AFP-L3百分比与GP73联合检测,阳性率明显高于AFP-L3百分比或GP73单项检测阳性率,差异有统计学意义(P<0.05);治疗后复检,AFPL3百分比阳性率和GP73阳性率均下降,差异均有统计学意义(P<0.05)。HCC患者治疗后血清中AFP-L3百分比由35.4%降至14.02%,而GP73则由243.13 ng/ml降至161.94 ng/ml,差异均有统计学意义(P<0.05)。结论 AFP-L3百分比与GP73联合检测诊断HCC,阳性率明显高于GP73或AFP-L3百分比单项检测。AFP-L3百分比和GP73检测可作为射频消融治疗HCC效果的有效判定指标。
Objective To evaluate the effect of detection of AFP-L3 and GP73 serum levels in response to radiofrequency ablation of primary hepatocellular carcinoma (HCC). Methods Thirty-four patients with primary liver cancer who had not been treated before admission were enrolled (group A), 46 patients with hepatitis and cirrhosis (group B) and 30 healthy subjects (group C). A group of patients after treatment review of 34 patients (D group). The contents of total AFP and AFP-L3 were detected to calculate the percentage of AFP-L3. Serum GP73 was determined by enzyme-linked immunosorbent assay. Results The percentage of AFP-L3 and GP73 detected before treatment in primary HCC patients was significantly higher than that of AFP-L3 or GP73 (P <0.05). After treatment, AFPL3 The percentage positive rate and GP73 positive rate decreased, the differences were statistically significant (P <0.05). The percentage of serum AFP-L3 in HCC patients decreased from 35.4% to 14.02%, while the GP73 decreased from 243.13 ng / ml to 161.94 ng / ml, with statistical significance (P <0.05). Conclusions The positive rate of AFP-L3 in combination with GP73 in diagnosis of HCC was significantly higher than that of GP73 or AFP-L3 percentage. Percentage of AFP-L3 and GP73 detection can be used as effective indicators for the treatment of HCC with radiofrequency ablation.